News | October 25, 2023
Sumitomo Pharma announces authorization in Canada of Orgovyx for treatment prostate cancer
Orgovyx is the first and only oral GnRH receptor antagonist approved for advanced prostate cancer in Canada
Orgovyx is the first and only oral GnRH receptor antagonist approved for advanced prostate cancer in Canada
New Molecular biology lab launched, AIIA increased its work scope in form of MoUs
Three block copolymers added to RESOMER portfolio of bioabsorbable polymers
Approval of oral, once-daily VELSIPITY based on favorable safety and efficacy data from the ELEVATE UC Phase 3 trials
_256_384.jpg)
GenWorks Health Introduces Braster Pro for breast screening & EVA for cervical screening in rural areas & communities
New effective carrier systems for drug delivery in different dosage applications including oral, topical & parenteral
Multi-million dollar investment augments in-vitro biology capabilities in primary and secondary screening
The composition of ORAAL is protected by a granted patent in India until November 2033
Astria will assume full cost and responsibility for the global development and commercialization of the licensed therapeutic program for all indications
Astellas stands on the forefront of healthcare change to turn innovative science into value for patients
Subscribe To Our Newsletter & Stay Updated
